Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MVC-COV1901 vs MVC-COV1901(Beta) Booster Study
NCT05216601Phase 1Completed
- Sponsor
- Medigen Biotechnology
- Start
- May 2022
- Primary completion
- Jul 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of MVC-COV1901 (Beta) in coronavirus disease 2019 (COVID-19) (3 arms), sponsored by Medigen Biotechnology. Primary endpoints: Incidence of Adverse Events and Primary Immunogenicity. Started May 2022; status: completed.
02
Drugs
MVC-COV1901 (Beta)
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05216601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05216601.